Ekatherine Asatiani

888 total citations
19 papers, 659 citations indexed

About

Ekatherine Asatiani is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Ekatherine Asatiani has authored 19 papers receiving a total of 659 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 7 papers in Hematology and 6 papers in Genetics. Recurrent topics in Ekatherine Asatiani's work include Fibroblast Growth Factor Research (4 papers), Acute Myeloid Leukemia Research (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Ekatherine Asatiani is often cited by papers focused on Fibroblast Growth Factor Research (4 papers), Acute Myeloid Leukemia Research (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Ekatherine Asatiani collaborates with scholars based in United States, Italy and France. Ekatherine Asatiani's co-authors include Edward P. Gelmann, Jeffrey E. Lancet, Lawrence D. Mayer, Christine E. Swenson, Jonathan E. Kolitz, Arthur C. Louie, Eric J. Feldman, Steven L. Allen, Alan F. List and Ellen K. Ritchie and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Ekatherine Asatiani

19 papers receiving 642 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ekatherine Asatiani United States	10	360	211	120	102	101	19	659
Jingcao Huang China	16	515 1.4×	126 0.6×	369 3.1×	81 0.8×	111 1.1×	51	907
Michael A. Dengler Germany	14	455 1.3×	49 0.2×	109 0.9×	58 0.6×	118 1.2×	24	706
Tatjana M.H. Niers Netherlands	10	195 0.5×	138 0.7×	126 1.1×	55 0.5×	82 0.8×	11	596
Shamudheen Mohammed Rafiyath United States	5	115 0.3×	93 0.4×	102 0.8×	67 0.7×	67 0.7×	7	432
Caner Saygin United States	10	426 1.2×	156 0.7×	337 2.8×	87 0.9×	66 0.7×	27	767
Natalia Baran United States	15	380 1.1×	244 1.2×	153 1.3×	51 0.5×	50 0.5×	62	679
Glenn Michelson United States	14	340 0.9×	146 0.7×	282 2.4×	83 0.8×	72 0.7×	51	668
Anna Korycka Poland	17	304 0.8×	162 0.8×	114 0.9×	338 3.3×	28 0.3×	51	781
Yanjie He China	16	384 1.1×	128 0.6×	317 2.6×	30 0.3×	33 0.3×	47	816
Joshua F. Zeidner United States	15	616 1.7×	637 3.0×	482 4.0×	162 1.6×	92 0.9×	90	1.3k

Countries citing papers authored by Ekatherine Asatiani

Since Specialization

Citations

This map shows the geographic impact of Ekatherine Asatiani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ekatherine Asatiani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ekatherine Asatiani more than expected).

Fields of papers citing papers by Ekatherine Asatiani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ekatherine Asatiani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ekatherine Asatiani. The network helps show where Ekatherine Asatiani may publish in the future.

Co-authorship network of co-authors of Ekatherine Asatiani

This figure shows the co-authorship network connecting the top 25 collaborators of Ekatherine Asatiani. A scholar is included among the top collaborators of Ekatherine Asatiani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ekatherine Asatiani. Ekatherine Asatiani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Prenen, Hans, Chrisann Kyi, Sandip Pravin Patel, et al.. (2021). 136P Phase I dose escalation study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1 in solid tumors. Annals of Oncology. 32. S1436–S1436. 7 indexed citations

Oh, Stephen T., Jean‐Jacques Kiladjian, Francesca Palandri, et al.. (2021). Abstract CT216: A Phase 1/2 Study of INCB000928 as Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104). Cancer Research. 81(13_Supplement). CT216–CT216. 1 indexed citations

Bibeau, Kristen, Luis Féliz, Scott Barrett, et al.. (2020). Progression-free survival in patients with cholangiocarcinoma with FGFR2 fusions or rearrangements: An exploration of response to systemic therapy.. Journal of Clinical Oncology. 38(4_suppl). 588–588. 2 indexed citations

Oh, Stephen T., Jason Gotlib, Sanjay Mohan, et al.. (2020). A Phase 1/2 Study of INCB000928 As Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104). Blood. 136(Supplement 1). 3–3. 5 indexed citations

Galsky, Matt D., Thomas Powles, Robert Dreicer, et al.. (2020). FIGHT-205: Phase II study of first-line pemigatinib (PEMI) plus pembrolizumab (PEMBRO) versus PEMI alone versus standard of care (SOC) for cisplatin (CIS)—Ineligible urothelial carcinoma (UC) with FGFR3 mutation or rearrangement.. Journal of Clinical Oncology. 38(6_suppl). TPS592–TPS592. 9 indexed citations

Bekaii‐Saab, Tanios, Juan W. Valle, Eric Van Cutsem, et al.. (2020). FIGHT-302: Phase III study of first-line (1L) pemigatinib (PEM) versus gemcitabine (GEM) plus cisplatin (CIS) for cholangiocarcinoma (CCA) with FGFR2 fusions or rearrangements.. Journal of Clinical Oncology. 38(4_suppl). TPS592–TPS592. 13 indexed citations

Necchi, Andrea, Damien Pouessel, Raya Leibowitz‐Amit, et al.. (2018). Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA). Annals of Oncology. 29. viii319–viii320. 41 indexed citations

Heist, Rebecca S., Leena Gandhi, Geoffrey I. Shapiro, et al.. (2013). Combination of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.. Journal of Clinical Oncology. 31(15_suppl). 2530–2530. 20 indexed citations

Infante, Jeffrey R., Leena Gandhi, Geoffrey I. Shapiro, et al.. (2012). Phase lb combination trial of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with locally advanced or metastatic solid tumors.. Journal of Clinical Oncology. 30(15_suppl). TPS3118–TPS3118. 8 indexed citations

10.

Naing, Aung, Philip Komarnitsky, A. Milner, et al.. (2012). 608 Phase I Dose-escalation Trial of a Selective Oral MEK1/2 Inhibitor, Pimasertib (MSC1936369B), Combined with an mTOR Inhibitor, Temsirolimus, in Patients with Advanced Solid Tumors. European Journal of Cancer. 48. 187–187. 5 indexed citations

11.

Feldman, Eric J., Jeffrey E. Lancet, Jonathan E. Kolitz, et al.. (2011). First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia. Journal of Clinical Oncology. 29(8). 979–985. 240 indexed citations

12.

Parikh, Sameer A., Hagop M. Kantarjian, Aaron D. Schimmer, et al.. (2010). Phase II Study of Obatoclax Mesylate (GX15-070), a Small-Molecule BCL-2 Family Antagonist, for Patients With Myelofibrosis. Clinical Lymphoma Myeloma & Leukemia. 10(4). 285–289. 69 indexed citations

13.

Cortes, Jörge E., Ronald Paquette, Moshe Talpaz, et al.. (2008). Preliminary Clinical Activity in a Phase I Trial of the BCR-ABL/IGF- 1R/Aurora Kinase Inhibitor XL228 in Patients with Ph++ Leukemias with Either Failure to Multiple TKI Therapies or with T315I Mutation. Blood. 112(11). 3232–3232. 43 indexed citations

14.

Feldman, Eric J., Jeffrey E. Lancet, Jonathan E. Kolitz, et al.. (2008). Phase I Study of a Liposomal Carrier (CPX-351) Containing a Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in Advanced Leukemias. Blood. 112(11). 2984–2984. 6 indexed citations

15.

Feldman, Eric J., Jeffrey E. Lancet, Jonathan E. Kolitz, et al.. (2007). Phase I Study of a Liposomal Carrier (CPX-351) Containing an Optimized, Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in Advanced Leukemias and Myelodysplastic Syndromes (MDS).. Blood. 110(11). 900–900. 7 indexed citations

16.

Asatiani, Ekatherine & Craig M. Kessler. (2007). Multiple congenital coagulopathies co‐expressed with Von Willebrand’s disease: the experience of Hemophilia Region III Treatment Centers over 25 years and review of the literature. Haemophilia. 13(6). 685–696. 18 indexed citations

17.

Asatiani, Ekatherine & Edward P. Gelmann. (2005). Targeted therapies for prostate cancer. Expert Opinion on Therapeutic Targets. 9(2). 283–298. 11 indexed citations

18.

Asatiani, Ekatherine, et al.. (2005). Deletion, Methylation, and Expression of the NKX3.1 Suppressor Gene in Primary Human Prostate Cancer. Cancer Research. 65(4). 1164–1173. 121 indexed citations

19.

Asatiani, Ekatherine, Philip Cohen, Metin Özdemirli, et al.. (2004). Monoclonal gammopathy in extranodal marginal zone lymphoma (ENMZL) correlates with advanced disease and bone marrow involvement. American Journal of Hematology. 77(2). 144–146. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact